Deutsche Bank downgraded Novartis to Hold from Buy with a price target of CHF 105, down from CHF 110, after the company said in its Q2 earnings presentation that it discontinued development of opnurasib in order to “prioritize other key programs.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- NVS Earnings: Novartis Beats Q2 Estimates, Raises Profitability Outlook
- Options Volatility and Implied Earnings Moves Today, July 18, 2024
- Novartis Q2 Sales Soar, Outlook Raised
- NVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 19, 2024